postponed the topic on permafrost
Unlike you, Janic reads ALL the article, what does it say? Clearly another announcement effect as it comes out regularly to attract subsidies.This time there is a vaccine against the Ebola virus
The rVSV-ZEBOV vaccine is expected to debut in the Ebola epidemic in the DRC. Provided, however, to overcome the challenges related to its transport and its conservation in inaccessible regions by plane or by car, often without electricity in the middle of the jungle
History is repeating itself, and that of the Ebola virus is the perfect illustration. Since the discovery of the virus in 1976 Zaire (...) scientific research is undertaken to develop a vaccine but are finally abandoned for lack of resources. The ninth documented occurrence of the virus, which has occurred in recent weeks with 39 suspected cases and has already killed 19 people, has an air of déjà-vu. Except that this time, a notable difference, there is a vaccine.! For the first time, the health agencies of the DRC could deploy a cure, the rVSV-ZEBOV (or VSV-EBOV), initially developed by the Agency of the Public Health of Canada and licensed by Merck Laboratories.
Read also: Ebola vaccine tested at HUG obtains good results in Guinea
Tested in several locations around the world, including the University Hospitals of Geneva (HUG), it demonstrated its ability to safely trigger the body's production of antibodies against the Ebola virus in phase clinical trials. I and II, in healthy volunteers. [*]
Encouraging results (sic) that had logically led to conducting phase III trials, on a larger scale and in people in contact with the virus. The rVSV-ZEBOV had then demonstrated an efficiency of the order of 75 100% in 7651 people according to The Lancet. Figures not obtained against placebo, for obvious ethical reasons, but during a so-called belt vaccination campaign, in which people came in direct contact with a diagnosed patient, as well as their own contacts (ie two degrees of separation) were vaccinated. [*] [*]
Although everything leads to believe, we are not yet sure that this vaccine will work in this situation
Laurent Kaiser, virologist
Another large clinical trial later in Guinea was conducted with 5837 people meeting these contact criteria and concludes with an 100% efficacy rate, with no case of Ebola occurring within 10 days the vaccination. In the process, a stock of 300 000 doses of rVSV-ZEBOV was set up in the event of a new outbreak thanks to the support of Gavi Alliance, a Geneva-based organization working to provide access to the poorest countries fast to expensive treatments.
Despite the effectiveness and availability of the vaccine, caution remains. "It remains to be confirmed whether these 39 cases are indeed cases of Ebola," says Laurent Kaiser, a virologist at HUG. There are many infectious diseases in the region with similar symptoms. And although the viruses of 2014 and 2018 belong to the same strain "Zaire", nothing guarantees for the moment the success of the vaccine. "In 2015, the clinical trials took place in a single study in Guinea, at the end of the epidemic and therefore after the emergency. Although everything leads us to believe, we are not yet sure that this vaccine will work in this situation, "says the doctor.
Storage at -80 ° C
For this reason, the rVSV-ZEBOV does not currently have any marketing authorization in the usual sense of the term. The World Health Organization (WHO) has developed an experimental protocol that has been validated by the health authorities and the ethics committees of the DRC, writes in an email to Time Tarik Jasarevic, spokesperson for the WHO. This green light will lead to a temporary authorization to place rVSV-ZEBOV on the market for a so-called compassionate use. [*] [*] [*]
Example at Ikoko Ipenge, a village where two cases occurred on May 13, and which is not connected to Bikoro, where the WHO has installed an 15 beds care center and a mobile laboratory, only after a difficult trip by motorcycle of about thirty kilometers through the jungle. As for the Bikoro airport, it is too poorly maintained to use it. "It's going to be complicated and expensive," said Peter Salama, the director of the WHO's Emergency Management Program, at a press conference in Geneva on May 11.
Even though logistics would be ideal and the vaccine ready in the field, the belt vaccination campaign is no sinecure: epidemiologists, data specialists and other health personnel must document the progress of the epidemic , trace all contacts of the patient, at two degrees of separation, in the three weeks preceding the diagnosis. A delicate detective work essential to the success of such a vaccination strategy. "The vaccine can change the game, but it will not be enough by itself: it requires a mobilization of communities and health personnel without forgetting to implement preventive actions," concludes Laurent Kaiser.
[*] any introduction of any product into an organism causes antibody production. Does the author of these articles ignore him?
Then on healthy carriers as if it was a demonstration of efficiency in patients.
[*] [*] history repeats the story every time, and it looks like the WHO report on smallpox, which concludes that "despite some successes in some countries, it was a failure in general"
[*] [*] [*] There it reminds, the H1N1 with all the circus that accompanied him and the simulacrum of vaccination Bachelot.
"We do science with facts, as is a house with stones, but an accumulation of facts is no more a science than a heap of stones is a house" Henri Poincaré
"Absence of evidence is not evidence of absence" Exnihiloest